利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.011 秒)

    Effervescent formulations comprising a phosphonate and methods for their preparation
    1.
    发明公开
    Effervescent formulations comprising a phosphonate and methods for their preparation 有权
    Efferveszenzformulierungen mit einem Phosphonat und Herstellungsverfahrendafür

    公开(公告)号：EP2283823A1

    公开(公告)日：2011-02-16

    申请号：EP09009791.6

    申请日：2009-07-29

    申请人： Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. ,  Tseti, Ioulia

    发明人： Tseti, Ioulia

    IPC分类号： A61K9/20 ,  A61K9/16

    CPC分类号： A61K9/0007 ,  A61K9/1611 ,  A61K9/2009

    摘要： The invention provides an effervescent pharmaceutical composition comprising a biphosphonate compound or its pharmaceutically acceptable salt, a carbonate source, an acid source, a divalent metal salt as humidity moderator and a divalent cation scavenger, wherein the molar ratio of divalent cation scavenger to humidity moderator is at least 0.8/1. This composition makes the production of effervescent formulations comprising biphosphonate compounds easier, since less stringent controls or even no control of environmental humidity conditions have to be carried out during the production of the product. Moreover, the final product is protected against the negative impact of humidity, which may induce disintegration during the shelf-life of the product.

    摘要翻译： 本发明提供了包含二膦酸盐化合物或其药学上可接受的盐，碳酸盐源，酸源，作为调湿剂的二价金属盐和二价阳离子清除剂的泡腾药物组合物，其中二价阳离子清除剂与湿度调节剂的摩尔比为 至少0.8 / 1。 该组合物使得包含双膦酸酯化合物的泡腾制剂的生产更容易，因为在产品生产期间必须进行不太严格的控制或甚至不控制环境湿度条件。 此外，最终产品可以防止潮湿的负面影响，这可能在产品的保质期内引起分解。

    Stable ready to use injectable paracetamol formulation
    5.
    发明公开
    Stable ready to use injectable paracetamol formulation 有权
    Stabile，gebrauchsfertige，injizierbare Paracetamolformulierung

    公开(公告)号：EP2389923A1

    公开(公告)日：2011-11-30

    申请号：EP10005258.8

    申请日：2010-05-19

    申请人： Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. ,  Tseti, Ioulia

    发明人： Tseti, Ioulia

    IPC分类号： A61K9/00 ,  A61K31/167 ,  A61K47/18 ,  A61K47/40 ,  A61K47/20

    CPC分类号： A61K9/0019 ,  A61K31/167 ,  A61K47/20 ,  A61K47/22 ,  A61K47/40

    摘要： The invention concerns a stable aqueous paracetamol solution for use in IV infusion comprising at least one stabilizing-dissolving compound for paracetamol in solution selected from the group consisting of cyclodextrins, at least one stabilizing compound bearing at least one thiol functional group and at least one stabilizing compound selected from the group consisting of Thiamine salts.

    摘要翻译： 本发明涉及一种用于IV输注的稳定的对乙酰氨基酚水溶液，其包含至少一种稳定溶解化合物，用于溶液中的对乙酰氨基酚，所述溶液选自环糊精，至少一种具有至少一个硫醇官能团的稳定化合物和至少一种稳定化 选自硫胺盐的化合物。

    Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent
    8.
    发明公开
    Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent 审中-公开
    用于局部应用的药物制剂含有硫糖铝，透明质酸，精氨酸，和天然润肤

    公开(公告)号：EP2810641A1

    公开(公告)日：2014-12-10

    申请号：EP14386014.6

    申请日：2014-05-30

    申请人： Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

    发明人： Tseti, Ioulia

    IPC分类号： A61K9/00 ,  A61K31/00 ,  A61K8/00

    CPC分类号： A61K9/006 ,  A61K9/0014 ,  A61K31/198 ,  A61K31/7024 ,  A61K31/728 ,  A61K2300/00

    摘要： The present application relates to topical preparations containing, based on the total weight of the composition:
    (A) 0.05-5.0 wt% sucralfate
    (B) 0.05-5.0 wt% hyaluronic acid or hyaluronate salt thereof
    (C) 0.05-5.0 wt% of a natural moisturizing agent (e.g. natural yogurt or yogurt derivatives or milk fermentation products or honey or honey products or mixtures thereof)
    (D) 0.05-5.0 wt% L-Arginine,
    (E) 80.0-98.0 wt% water And
    (F) 1.0-15.0 wt% of a carrier or vehicle, other than water.
    These preparations are stable and show rheological properties comparable to the ones of the compositions that are already in the market for similar uses, while the healing time is shorter and / or the clearance of skin lesions is of a higher degree and therefore, these combinations are useful in treating diseases or disorders of the skin or the oral cavity.

    摘要翻译： 本申请涉及包含，基于组合物的总重量，局部用制剂：（A）0.05-5.0重量％的硫糖铝（B）0.05-5.0％（重量）透明质酸或其盐的透明质酸（C）为0.05〜5.0重量％的 天然保湿剂（例如天然酸奶或酸奶的衍生物或乳发酵产品或蜂蜜或蜂蜜产品或它们的混合物）（D）0.05-5.0％（重量）L-精氨酸，（E）80.0-98.0％（重量）水和（F）1.0 载体或媒介物，除了水以外的-15.0％（重量）。 这些准备工作是稳定的，并显示流变性能堪比组合物的那些确实已经在市场上类似的用途，而愈合时间短和/或皮损的清除程度较高，因此，本文的组合是 治疗皮肤或口腔的疾病或病症是有用的。

    Stable pharmaceutical dosage forms comprising Levothyroxine sodium
    9.
    发明公开
    Stable pharmaceutical dosage forms comprising Levothyroxine sodium 审中-公开
    Stabile pharmazeutische Darreichungsformen enthaltend Levothyroxine Natrium

    公开(公告)号：EP2932963A1

    公开(公告)日：2015-10-21

    申请号：EP14001400.2

    申请日：2014-04-16

    申请人： Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

    发明人： Tseti, Ioulia

    IPC分类号： A61K9/20 ,  A61K47/38 ,  A61K31/198

    CPC分类号： A61K9/2054 ,  A61K31/198

    摘要： The present invention relates to a novel and stable levothyroxine sodium pharmaceutical composition and belongs to the technical field of pharmaceutical preparation and in particular to a levothyroxine sodium tablets. In the current invention, the levothyroxine sodium dosage forms comprise as active ingredient levothyroxine sodium in an amount of about 0.01% w/w to about 1% w/w and as excipients Microcrystalline cellulose in an amount of 80% w/w to 95% w/w , disintegrant in an amount of 5% w/w to 10% w/w , glidant in an amount of 0.5% w/w to 3% w/w , and lubricant in an amount of 0.5% w/w to 2% w/w .
    The proposed composition by improving the stability and the dissolution of the preparation can benefit the clinical application.
    Finally, the present invention is directed to therapeutic agents for treatment of hormone disorders and relates to stable pharmaceutical dosage forms of Levothyroxine sodium.

    摘要翻译： 本发明涉及一种新型稳定的左旋甲状腺素钠药物组合物，属于药物制剂的技术领域，特别涉及左甲状腺素钠片剂。 在本发明中，左甲状腺素钠剂型包含约0.01％w / w至约1％w / w的作为活性成分的左旋甲状腺素钠和作为赋形剂的80％w / w至95％的微晶纤维素， w / w，崩解剂的量为5％w / w至10％w / w，助流剂的量为0.5％w / w至3％w / w，润滑剂的量为0.5％w / w至 2％w / w。 通过提高制剂的稳定性和溶解度提出的组合物可以有益于临床应用。 最后，本发明涉及用于治疗激素紊乱的治疗剂，并涉及左甲状腺素钠的稳定的药物剂型。

    Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same
    10.
    发明公开
    Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same 审中-公开
    艾森 - （III）-Hydroxidkomplexe mit aktivierten Glucosesirups und Verfahren zur Herstellung davon

    公开(公告)号：EP2997968A1

    公开(公告)日：2016-03-23

    申请号：EP14386023.7

    申请日：2014-09-22

    申请人： Tseti, Ioulia

    发明人： Tseti, Ioulia

    IPC分类号： A61K31/295 ,  A61K31/7004

    CPC分类号： A61K33/26 ,  A61K31/295 ,  A61K31/7004 ,  A61K47/69

    摘要： The present invention generally relates to iron (III) carbohydrate complexes and to processes for the manufacture thereof. The product obtainable according to the method of the present invention may be safely used to the general population or animals in the therapy of iron deficiency. The process of the invention includes the steps of (i) providing an aqueous solution of glucose syrup having a certain dextrose equivalent (DE), (ii) adding one or more oxidizing bleaching agents, thereby obtaining the activated glucose syrup; (iii) converting said activated glucose syrup into a complex with iron (III) hydroxide; and (iv) obtaining a complex of iron (III) hydroxide and activated glucose syrup.

    摘要翻译： 本发明一般涉及铁（III）碳水化合物复合物及其制备方法。 根据本发明的方法可获得的产品可以安全地用于一般人群或动物治疗铁缺乏症。 本发明的方法包括以下步骤：（i）提供具有一定葡萄糖当量（DE）的葡萄糖浆水溶液，（ii）加入一种或多种氧化漂白剂，从而得到活化葡萄糖浆; （iii）将所述活化的葡萄糖浆与氢氧化铁（III）转化成络合物; 和（iv）获得氢氧化铁（III）和活化葡萄糖浆的络合物。